Yokomi Hiroshi

Dr. Yokomi Hiroshi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TWTomoyuki Watanabe
Tomoyuki Watanabe
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
YNYuko Noda
Yuko Noda
SNSoshi Narasaki
Soshi Narasaki
AMAtsushi Morio
Atsushi Morio
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background. We investigated the potential safety of remimazolam and propofol in malignant hyperthermia‐ (HM‐) susceptible patients using ryanodine receptor 1‐ (RYR1‐) expressing human embryonic kidney‐ (HEK‐) 293 cells. Methods. We compared the enhanced responsiveness of HEK‐293 cells expressing wild‐type RYR1 with that of mutant RYR1 to caffeine following perfusion with remimazolam or propofol. Furthermore, we investigated whether RYR1 enhanced the responsiveness of cells to remimazolam or propofol and compared the median effective concentration (EC50; i.e., the concentration required to reach half‐maximal activation) using an unpaired two‐tailed t‐test while a P < 0.05 was considered significant. Results. Remimazolam and propofol did not promote the caffeine‐induced increase in intracellular Ca2+ levels in HEK‐293 cells expressing mutant RYR1 even with exposure to approximately 100‐fold the clinically used concentration. In wild‐type RYR1, EC50 values of remimazolam following refusion vs. nonperfusion were 2.86 mM vs. 2.75 mM (P = 0.76) while for propofol perfusion vs. nonperfusion, they were 2.76 mM vs. 2.75 mM, respectively (P = 0.83). In mutant RYR1, EC50 values of remimazolam refusion vs. nonperfusion were 1.58 mM vs. 1.71 mM, respectively (P = 0.63) while for propofol perfusion vs. nonperfusion, they were 1.65 mM vs. 1.71 mM, respectively (P = 0.73). Remimazolam and propofol increased intracellular Ca2+ levels in a concentration‐dependent manner, but the effect was not enhanced by RYR1. EC50 values of remimazolam with non‐RYR1 vs. wild‐type RYR1 were 1.00 mM vs. 0.92 mM, respectively (P = 0.91) while those of propofol were 1.09 mM vs. 1.05 mM, respectively (P = 0.84). Conclusions. The increase in intracellular Ca2+ concentration caused by remimazolam or propofol was not considered an RYR1‐mediated reaction. We conclude that remimazolam and propofol can be safely used as an anesthetic in MH‐susceptible patients with RYR1‐mutation without causing MH and may be safely substituted for an MH‐triggering anesthetic when RYR1‐mediated MH occurs.

21 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
YHYokomi Hiroshi
Yokomi Hiroshi
TKTakahiro Kato
Takahiro Kato
SNSoshi Narasaki
Soshi Narasaki
SKSatoshi Kamiya
Satoshi Kamiya
STShima Taguchi
Shima Taguchi
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Refractory peripheral neuropathy can occur as a side effect in 60–70% of patients receiving Paclitaxel (PTX). Yokukansan (YKS) is a Japanese herbal medicine reported to have analgesic properties for entrapment nerve injuries. Therefore, we investigated the anti-allodynic effect of Yokukansan on Paclitaxel-induced neuropathic pain. All experiments used 6-week-old male Sprague Dawley rats. Mechanical allodynia was evaluated using a dynamic plantar aesthesiometer. A mobile touch-stimulator unit applied progressively increasing force to the mid-plantar region of the hind paw in a vertical direction until the animal withdrew its paw. This was carried out before the Paclitaxel administration and during the first, second, third, and fourth weeks. Using a rat model of PTX-induced neuropathic pain (PTX rat), we injected PTX (intraperitoneally, 2 mg/kg) five times every 2 days. Using the dynamic plantar test, we evaluated the anti-allodynic effect of YKS (orally administered, 1 g/kg). YKS administration on a daily basis significantly enhanced the withdrawal threshold in PTX rats and reduced the expression level of activated microglia immunostaining with Iba1, a specific marker for microglia. The intrathecal administration of WAY-100635 (5-hydroxytryptamine [5-HT]1A receptor antagonist) and Ketanserin (5-HT2A/2C receptor antagonist) inhibited the protective effects of YKS. YKS exhibited an anti-allodynic effect in a rodent model of PTX-induced neuropathic pain by reducing the sensitivity to pain stimuli. These results suggest that Yokukansan may activate 5-HT receptors in the spinal cord, mediating Paclitaxel-induced neuropathic pain.

Verified
Journal Article
Open access
PDF file
YKYoko Kajikawa
Yoko Kajikawa
YHYokomi Hiroshi
Yokomi Hiroshi
SNSoshi Narasaki
Soshi Narasaki
SKSatoshi Kamiya
Satoshi Kamiya
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background: Diabetic neuropathic pain is a known complication of diabetes mellitus (DM) and results from the complex interaction of various factors affecting the nervous system. Yokuansan (YKS) is a versatile traditional Japanese herbal medicine with a wide range of applications, especially in pain management and neurological manifestations. YKS has analgesic properties for nerve damage and is a potential treatment for DM-induced neuropathic pain, especially in patients with diabetic neuropathy. Thus, we examined the anti-allodynic effect of YKS on DM-induced neuropathic pain. Methods: All experiments were performed on 6-week-old male Sprague–Dawley rats. DM and diabetic neuropathy were induced in rats with streptozotocin. Mechanical allodynia was assessed using dynamic plantar esthesiometry. Additionally, we conducted an immunological assessment of microglia cell changes in the spinal cord and an experiment to clarify the involvement of serotonin. Results: Diabetes significantly reduced withdrawal thresholds in rats during the initial two weeks of the experiment, which stabilized thereafter. However, this effect was not investigated in the control group. We assessed, using the dynamic plantar test, the anti-allodynic effects of orally administered YKS (1 g/kg). Daily YKS administration significantly increased the withdrawal threshold in DM animals. Additionally, oral YKS reduced the expression of Ibal-1-positive microglia. To elucidate the mechanism of action of YKS, we explored the involvement of serotonin (5-hydroxytryptamine [5-HT]) receptors in mediating its effects. Intrathecal administration of 5-HT receptor antagonists (WAY-100635, ketanserin, and ondansetron) inhibited the protective effects of YKS. Conclusions: YKS exhibited an anti-allodynic effect, suggesting that YKS may activate 5-HT receptors in the spinal cord, thereby alleviating diabetic neuropathic pain.